462 related articles for article (PubMed ID: 19417561)
1. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
[TBL] [Abstract][Full Text] [Related]
2. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
4. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
5. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
[TBL] [Abstract][Full Text] [Related]
6. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
8. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
Ou WB; Zhu MJ; Demetri GD; Fletcher CD; Fletcher JA
Oncogene; 2008 Sep; 27(42):5624-34. PubMed ID: 18521081
[TBL] [Abstract][Full Text] [Related]
10. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
11. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
13. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
[TBL] [Abstract][Full Text] [Related]
15. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
[TBL] [Abstract][Full Text] [Related]
20. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
